Skip to the main content

Signa vitae : journal for intesive care and emergency medicine, Vol. 6 No. 2, 2011.

Original scientific paper

Nesiritide and clinically relevant outcomes in cardiac surgery: a meta-analysis of randomized studies

GIULIA MAJ orcid id orcid.org/0000-0002-8594-5980 ; Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Via Olgettina 60 Milano, 20132 Italy
GIOVANNI LANDONI ; Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Via Olgettina 60 Milano, 20132 Italy
GIUSEPPE BIONDI-ZOCCAI ; Interventional Cardiology, Division of Cardiology, University of Turin, Turin, Italy
ELENA BIGNAMI ; Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Via Olgettina 60 Milano, 20132 Italy
LUCA CABRINI ; Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Via Olgettina 60 Milano, 20132 Italy
LUCA BURATTI ; Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Via Olgettina 60 Milano, 20132 Italy
MASSIMILIANO GRECO ; Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Via Olgettina 60 Milano, 20132 Italy
MASSIMO ZAMBON ; Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Via Olgettina 60 Milano, 20132 Italy
ALBERTO ZANGRILLO ; Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Via Olgettina 60 Milano, 20132 Italy

Full text: english pdf 143 Kb

page 17-23

downloads: 682

cite

Abstract

B-type natriuretic peptide is a cardiac hormone that relaxes vascular smooth muscle and causes arterial dilatation. Nesiritide has been associated with increased urine output; reduced diuretic requirements; and suppression of aldosterone, endothelin, and norepinephrine. We have independently conducted the first systematic review and meta-analysis of randomized trials to determine the impact of nesiritide on renal replacement therapy and death in patients undergoing cardiac surgery. We performed a meta-analysis of 6 randomized controlled studies including 560 patients (280 receiving nesiritide and 280 assigned to the control group). Two unblinded reviewers selected randomized trials studying nesiritide in patients undergoing cardiac surgery. Nesiritide doses ranged from 0.005 mcg/kg/min to 0.01 mcg/kg/min. Nesiritide did not reduce postoperative creatinine peak values: -0.16 [-0.42, 0.10], p for effect=0.23, p for heterogeneity<0.01, I2=90.5%) or the need for renal replacement therapy (1/177 in the nesiritide group vs 4/176 in the control group OR 0.39 [0.07, 2.06], p for effect=0.27, p for heterogeneity=0.70, I2=0%). We observed an interesting trend toward a reduction in mortality in the nesiritide group:13/280 (4.6%) vs 22/280 (7.8%) OR 0.57 [0.28, 1.15], p for effect=0.12, p for heterogeneity=0.43, I2=0%. Nesiritide did not reduce time of mechanical ventilation -8.77 hours [-21.42, 3.88], p=0.17, length of hospital stay -2.67 days [-6.50, 1.16], p=0.17 or intensive care unit (ICU) stay -0.94 days [-2.83, 0.95], p=0.33. In conclusion, further randomized controlled trials are needed to support the hypothesis that nesiritide improves clinically relevant outcomes in cardiac surgery.

Keywords

Nesiritide; meta-analysis; cardiac surgery; renal replacement therapy; mortality

Hrčak ID:

73077

URI

https://hrcak.srce.hr/73077

Publication date:

1.10.2011.

Visits: 1.476 *